Nuvo Research Inc  

(Public, TSE:NRI)   Watch this stock  
Find more results for NRI
5.09
+0.09 (1.80%)
Delayed:   10:01AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 5.00 - 5.09
52 week 1.58 - 5.73
Open 5.00
Vol / Avg. 1,785.00/56,339.00
Mkt cap 52.96M
P/E     -
Div/yield     -
EPS -1.09
Shares 10.40M
Beta 0.31
Inst. own     -
Sep 9, 2014
Nuvo Research Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -59.72% -56.37%
Operating margin -56.20% -56.67%
EBITD margin - -11.76%
Return on average assets -45.12% -41.42%
Return on average equity -81.82% -61.65%
Employees 79 -
CDP Score - -

Address

Unit 10, 7560 Airport Road
MISSISSAUGA, ON L4T 4H4
Canada
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)

Website links

Description

Nuvo Research Inc. is a specialty pharmaceutical company. The Company is engaged in building a portfolio of products for the treatment of pain through internal research and development (R&D), in-licensing and acquisition. The Company�s product portfolio includes Pliaglis and Synera. Through its subsidiary Nuvo Research AG, the Company is also developing the compound WF10, for the treatment of immune related diseases. The Company�s Pain Group located in West Chester, Pennsylvania is focused on the development and commercialization of topically delivered pain products, including Pennsaid.

Officers and directors

Daniel H. Chicoine Chairman of the Board, Co-Chief Executive Officer
John C. London President, Co-Chief Executive Officer, Director
Stephen L. Lemieux Chief Financial Officer, Vice President
Henrich R. K. Guntermann M.D. President of Europe and Immunology Group, Director
Bradley S. Galer M.D. President of Pain Group
Age: 52
Katina Loucaides Vice President, General Counsel, Secretary
David A. Copeland Lead Independent Director
Anthony E. Dobranowski Independent Director
Jacques Messier Independent Director
Theodore H. Stanley M.D. Independent Director
Age: 73